Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | PREP | P48147 | 3/20 | 0.51 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1122261 | 0.96 | PREP (0.55) | SMN1; SMN2NPC1RAB9APREPKMT2A | |
| SCHEMBL1122258 | 0.96 | PREP (0.55) | SMN1; SMN2NPC1RAB9APREPKMT2A | |
| SCHEMBL80752 | 0.88 | SPHK2 (0.54) | SMN1; SMN2NPC1RAB9APREPFKBP1A | |
| SCHEMBL3605585 | 0.88 | SPHK2 (0.54) | SMN1; SMN2NPC1RAB9APREPFKBP1A | |
| SCHEMBL1190565 | 0.88 | SPHK2 (0.54) | SMN1; SMN2NPC1RAB9APREPFKBP1A | |
| SCHEMBL13375648 | 0.87 | PREP (0.49) | SMN1; SMN2NPC1RAB9APREPFKBP1A | |
| SCHEMBL13961188 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9APREPFKBP1A | |
| SCHEMBL13198885 | 0.87 | NPC1 (0.60) | SMN1; SMN2NPC1RAB9APREPFKBP1A | |
| SCHEMBL5305188 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9APREPFKBP1A | |
| SCHEMBL14646609 | 0.87 | NPC1 (0.60) | SMN1; SMN2NPC1RAB9APREPFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920038-B2 | Methyl oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920038-B2 | Methyl oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170260177-A1 | METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260177-A1 | METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-09-14 | — | — | US | disclosed |
| WO-2016089721-A1 | METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| US-7943645-B2 | Piperidine compounds for use as orexin receptor antagonist | SMITHKLINE BEECHAM LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20090082390-A1 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. | 2009-03-26 | — | — | US | disclosed |
| US-7423052-B2 | Piperidine compounds for use as orexin receptor antagoinst | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-09-09 | — | — | US | disclosed |
| EP-1406897-B1 | COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2007-03-14 | — | — | EP | disclosed |
| US-20040215014-A1 | Piperidine compounds for use as orexin receptor antagonist | SMITHKLINE BEECHAM LIMITED (GB) | 2004-10-28 | — | — | US | disclosed |
| EP-1406897-A2 | COMPOUNDS | SmithKline Beecham plc (GB) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003002559-A2 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-01-09 | — | — | WO | disclosed |
| EP-0670310-B1 | Bisulfite adducts of arginine aldehydes useful as thrombin inhibitors and as anticoagulants | LILLY CO ELI (US) | 1998-09-02 | — | — | EP | disclosed |
| EP-0671390-A2 | Antithrombotic agents | ELI LILLY AND COMPANY (US) | 1995-09-13 | — | — | EP | disclosed |
| EP-0670310-A1 | Bisulfite adducts of arginine aldehydes useful as thrombin inhibitors and as anticoagulants | ELI LILLY AND COMPANY (US) | 1995-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082390-A1 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | HCRTR2, HCRTR1, OXTR | SMN1; SMN2 3381/4885NPC1 1015/4885RAB9A 1592/4885 |
| US-20170260177-A1 | METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | SMN1; SMN2 1886/4885NPC1 1393/4885RAB9A 3473/4885 |
| US-20040215014-A1 | Piperidine compounds for use as orexin receptor antagonist | HCRTR2, HCRTR1, OXTR | SMN1; SMN2 3363/4885NPC1 706/4885RAB9A 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.